Health Discovery

Health Discovery FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Health Discovery (HDVY) as of Oct 15, 2026 is 181.69 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 141.11 % — a change of 28.76% (higher).

FCF Conversion

181.69 %

YoY

28.76%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Health Discovery is 2020 181.69 % . FCF Conversion Rate (FCF/EBITDA) of Health Discovery was 2019 141.11 % . It decreases by 28.76% higher compared to the previous year.

The Health Discovery FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
-416.76 USD
Jan 1, 2015
103.67 USD
Jan 1, 2016
22.53 USD
Jan 1, 2017
35.93 USD
Jan 1, 2018
34.64 USD
Jan 1, 2019
141.11 USD
Jan 1, 2020
181.69 USD
The Health Discovery FCF Conversion history
YEARFCF ConversionYoY
181.69 %+28.76%
141.11 %+307.38%
34.64 %-3.60%
35.93 %+59.52%
22.53 %-78.27%
103.67 %-124.88%
-416.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health Discovery Stock analysis

What does Health Discovery do? Health Discovery Corp (HDC) is a company specializing in the development of novel diagnostic technologies for cancer early detection and prevention. The company was founded in 2003 and is headquartered in Savannah, Georgia. History HDC began its operations as a research laboratory at the University of Georgia and the Georgia Institute of Technology. Since then, the company has developed numerous patents and technologies, including a new method for identifying gene expression profiles and the development of data mining software that allows for the identification of genetic patterns associated with various types of cancer. Business model HDC's business model is based on the development and commercialization of diagnostic tests and screening tools that help physicians and patients identify cancer at an early stage. The company works closely with research and development departments at hospitals and universities to develop and bring new technologies and tests to market. Segments HDC has divided itself into different segments to focus on specific technologies and applications. The key segments of HDC are: 1. Biomarker development: This segment of HDC focuses on the identification of biomarkers that can serve as markers for the presence of cancer in the body. 2. Women's health products: HDC has developed products and tests specifically targeting women, including a blood test for early detection of ovarian cancer and a digital breast examination device to improve breast cancer diagnostics. 3. Software solutions: HDC has developed data mining software that can identify genetic patterns associated with specific types of cancer. The software is used by researchers and scientists in cancer research. Products The company has developed a range of innovative products to help physicians and patients detect cancer at an early stage and take preventive measures. Some of HDC's key products include: 1. MelApp: A smartphone app that allows users to take photos of skin lesions or moles and analyze them for the presence of melanomas. 2. VitalSines BodyTel: A digital breast examination device designed to help physicians detect breast cancer at an early stage by identifying changes in breast structure and density. 3. Ovarian Cancer Early Detection Test: A blood test specifically targeting the early detection of ovarian cancer, with high accuracy. In summary, HDC specializes in the development of innovative technologies for cancer prevention and early detection. The company works closely with academic and clinical research and has specialized in various technologies and applications, including biomarker development, women's health products, and software solutions. Some of the company's key products include MelApp, VitalSines BodyTel, and the Ovarian Cancer Early Detection Test. Health Discovery is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health Discovery stock

FCF Conversion Rate (FCF/EBITDA) of Health Discovery is 181.69 % in 2020.

FCF Conversion Rate (FCF/EBITDA) of Health Discovery changed from 141.11 % to 181.69 %, representing a 28.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Health Discovery since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Health Discovery with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Health Discovery

All Key Metrics — Health Discovery